Stock Research Monitor: PCRX, SCYX, and MDCO
LONDON, UK / ACCESSWIRE / July 2, 2018 / If you want a free Stock Review on MYL sign up now at www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com assesses Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), SCYNEXIS Inc. (NASDAQ: SCYX), and The Medicines Co. (NASDAQ: MDCO). The biggest catalyst of the Generic Drugs industry is the significantly lower price of generics compared to branded drugs. Although generics are chemically identical to their branded counterparts, they are typically sold at substantial discounts from the branded price. All you have to do is sign up today for this free limited time offer by clicking the link below.
Canonsburg, Pennsylvania headquartered Mylan N.V.'s stock finished last Friday's session 0.52% lower at $36.14. A total volume of 2.56 million shares was traded. The Company's shares are trading below their 50-day moving average by 7.23%. Additionally, shares of Mylan, which together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide, have a Relative Strength Index (RSI) of 32.32.
On June 18th, 2018, Mylan announced the US launch of Bivalirudin for Injection, 250 mg single-dose vial, a generic version of Angiomax® from The Medicines Company. The product is a direct thrombin inhibitor indicated for use as an anticoagulant in patients. Get the full research report on MYL for free by clicking below at:
On Friday, shares in Parsippany, New Jersey headquartered Pacira Pharmaceuticals Inc. ended the session 3.22% higher at $32.05. The stock recorded a trading volume of 486,571 shares. The Company's shares have gained 16.55% in the previous three months. The stock is trading 8.35% below its 50-day moving average. Moreover, shares of Pacira Pharma, which develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the US, have an RSI of 39.77.
On June 19th, 2018, Pacira Pharma and Nuance Biotech Co. Ltd announced that they have entered into an agreement to advance the development and commercialization of EXPAREL® (bupivacaine liposome injectable suspension) in China. EXPAREL is a non-opioid option for achieving long-lasting pain control after surgery via infiltration into the surgical site or administration as an interscalene brachial plexus nerve block. Access the free research report on PCRX now by signing up at:
Jersey City, New Jersey headquartered SCYNEXIS Inc.'s shares declined slightly by 0.61%, closing the session at $1.64 with a total trading volume of 495,728 shares. The stock has gained 24.24% over the previous three months. The stock is trading 6.66% above their 50-day moving average. Additionally, shares of SCYNEXIS, which develops and commercializes anti-infectives to address unmet therapeutic needs, have an RSI of 47.27.
On June 06th, 2018, SCYNEXIS announced the publication of results from a Phase-1 study of SCY-078, assessing the risk for drug-drug interactions when administered with drugs metabolized by the CYP family of enzymes, in The Journal of Clinical Pharmacology. SCY-078, the first representative of a novel oral and intravenous triterpenoid antifungal family, is in clinical development for the treatment of multiple serious fungal infections, including vulvovaginal candidiasis, invasive candidiasis, invasive aspergillosis, and refractory invasive fungal infections.
On June 27th, 2018, research firm Maxim Group initiated a 'Buy' rating on the Company's stock, with a target price of $6 per share. Are you already registered with Wall St. Equities? Do so now for free, and get the report on SCYX at:
Last Friday at the close, shares in Parsippany, New Jersey-based The Medicines Co. recorded a trading volume of 1.11 million shares, which was above their three months average volume of 773,500 shares. The stock ended the session 5.79% higher at $36.70. The Company's shares have advanced 8.39% in the past month and 16.43% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 11.68% and 15.65%, respectively. Furthermore, shares of Medicines Co., which provides medicines to treat acute and intensive care patients, have an RSI of 61.91.
On June 07th, 2018, research firm B. Riley FBR, Inc. initiated a 'Buy' rating on the Company's stock, with a target price of $55 per share.
On June 27th, 2018, Medicines Co. announced that the Independent Data Monitoring Committee (IDMC) for the ongoing inclisiran Phase-III trials has recommended that the trials continue as designed and conducted, without modification. The IDMC's recommendation was based on its planned review of unblinded safety and efficacy data from the trials. Aspiring Member, please take a moment to register below for your free research report on MDCO at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities